idec

Welcome to the 'idec' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'idec'.

Latest blogosphere posts tagged “idec”

• New Faces, New Vacancies on Biogen Idec Board May Foretell Another Proxy Battle

  
  Xconomy — Authority: 663
  Biotech , people , Drugs Luke Timmerman wrote: The Biogen Idec boardroom has seen a lot of turnover in the past few months, and who ends up filling the empty slots could say a lot about whether the Cambridge, MA-based biotech company (NASDAQ: BIIB ) will have another proxy fight with billionaire ...
  2 days ago

• (BIIB) Biogen’s Rheumatoid Arthritis Candidate Effective

  
  Stock Blog Hub — Authority: 458
  Biogen Idec ( BIIB ) and Genentech Inc., a wholly owned member of the Roche Group ( RHHBY ), recently reported positive phase III results on their rheumatoid arthritis (RA) candidate, ocrelizumab. Results from the study (STAGE) showed that the humanized anti-CD20 monoclonal antibody, when given in combination with ...
  2 days ago

• (FACT) Facet Biotech Rejects Biogen Idec Again

  
  Stock Blog Hub — Authority: 458
  Facet Biotech Corp. ( FACT ) once again rejected Biogen Idec Inc .’s ( BIIB ) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech’s stockholders. Earlier this month, Biogen had come back with a revised ...
  6 days ago

• Biogen Idec names new chairman, announces positive drug test results

  
  BloggingStocks — Authority: 675
  Filed under: Good news , Products and services , Lilly (Eli) (LLY) Biogen Idec ( BIIB ) has made a bit of news the past two days, starting with Thursdays news that William Young is the companys new chairman of the board . BIIBs Bruce Ross will complete his term as director and will step down from the board at ...
  6 days ago

• Up And Down The Ladder… Job Changes

  
  Pharmalot — Authority: 527
  Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others . That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the ...
  6 days ago

• 5AM Gathers $200M Fund, Advanced Cell Technology Advances with $2.8 Million, Gloucester Picked up for $640M, & More Boston-Area Deals News

  
  Xconomy — Authority: 663
  Roundup , deals , VC Rebecca Zacks wrote: Lots of deals to report this week from New England tech and life sciences companies. —Gloucester Pharmaceuticals of Cambridge, MA, agreed to an acquisition by Summit, NJ-based Celgene (NASDAQ: CELG ). Gloucester will get $340 million in cash, plus $300 million ...
  6 days ago

• Biogen Idec Chairman Steps Down as Board Re-Shuffles in Wake of Icahn Arrival

  
  Xconomy — Authority: 663
  Biotech , people , Politics Luke Timmerman wrote: Bruce Ross, one of the lightning rods for criticism from billionaire investor Carl Icahn during last spring’s proxy battle at Biogen Idec, has agreed to relinquish the company chairmanship and leave the board at next year’s annual meeting in what ...
  6 days ago

• PWRM, BIIB, FACT, DrStockPick.com Stock Report! Power 3 Medical Products Inc., Biogen Idec Inc. and Facet Biotech Corporation

  
  CRWE NEWS Financial Stock Market Website — Authority: 146
  Dr Stock Pick HOT News & Alerts!_________________________________________FREE Daily Stock Alerts From DrStockPick.com_________________________________________Thursday Dec. 10, 2009DrStockPick.com Stock Report!PWRM, BIIB, FACT**************************************************************PWRM, Power 3 Medical ...
  1 week ago

• Facet Rejects Biogen’s Latest Offer

  
  Xconomy — Authority: 663
  Life Sciences , deals , buyouts Rebecca Zacks wrote: The board of Redwood City, CA-based Facet Biotech (NASDAQ: FACT ) unanimously recommended that shareholders reject the latest tender offer from Cambridge, MA-based Biogen Idec (NASDAQ: BIIB ), saying that the $17.50 per-share offer, which would value ...
  1 week ago

• Zogenix Raises Cash for Headaches, Sleepless in Somaxon, Dow Chemical Spins Out Pfēnex, & More San Diego Life Sciences News

  
  Xconomy — Authority: 663
  Roundup , Life Sciences , deals Bruce V. Bigelow wrote: From Adamis to Zogenix, we’ve got the A to Z in San Diego life sciences news. Here’s your chance to catch up now. — Zogenix said it has raised a total of $71 million for the anticipated launch in January of its needle-free, drug-and-device ...
  1 week ago

• Acceleron Pharma Invests in Bricks & Mortar When Virtual is In Vogue

  
  Xconomy — Authority: 663
  Biotech , Drugs , Manufacturing Luke Timmerman wrote: Acceleron Pharma had to be kidding, I figured, when it scheduled me to visit their labs and offices a few weeks ago in Cambridge, MA. They insisted that I take a walking tour of their biotech drug factory. Why is that unusual? Quite a few biotech ...
  1 week ago

• Fact Biotech: Open for bidding

  
  TodaysFinancialNews.com LLC — Authority: 434
  The biotech sector has been a hot one this year. That’s good news for the companies on the auction block and bad news for the bidders. By Andrew Snyder, TodaysFinancialNews.com Baltimore – ( TFN ): There’s no doubt it has been a strong year for the nation’s biotech sector. The industry known for its ...
  1 week ago

• Biogen Idec’s Dream: Antibodies That Kill Two Birds With One Stone

  
  Xconomy — Authority: 663
  Biotech , cancer , Antibodies Luke Timmerman wrote: Some of the most successful biotech drugs ever created are designed to hit just one specific target on diseased cells, while sparing all sorts of markers found on healthy cells. But if Biogen Idec scientist Tony Manning and his colleagues are right, ...
  1 week ago

• A Graceful Exit for Gloucester, Pink Slips at Sermo, A Half a Billion Bucks for Vertex, & More Boston-Area Life Sciences News

  
  Xconomy — Authority: 663
  Roundup , Life Sciences , acquisitions Rebecca Zacks wrote: New England’s life sciences firms and their investors seemed to be exchanging some early holiday gifts this week. —Vertex (NASDAQ: VRTX ) completed t he latest in a string of large financing and licensing deals . In this one, the Cambridge, ...
  1 week ago

• Pharmalot… Pharmalittle… The Weekend Nears

  
  Pharmalot — Authority: 527
  Good morning again and nice to see you. A busy day is expected and so we are studying our to-do list as another deadline looms. Meanwhile, we are also looking ahead to the weekend. Our leaves are finally gone, which means there will be more time to cavort with the short and not-so-short people. And we look forward to ...
  1 week ago

• Biogen Fattens Offer to Buy Facet Biotech

  
  Xconomy — Authority: 663
  Life Sciences , deals , buyouts Ryan McBride wrote: Cambridge, MA-based Biogen Idec reports today that it’s upping its bid to buy Facet Biotech by 21 percent, after the smaller firm’s board rejected Biogen’s earlier buyout offer in October . Biogen (NASDAQ: BIIB ) said it would pay $17.50 per ...
  1 week ago

• (BMRN) BioMarin Pharmaceutical Earns Orphan Status From FDA

  
  Stock Blog Hub — Authority: 458
  Recently, BioMarin Pharmaceutical Inc. ( BMRN ) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug status to its candidate 3,4-diaminopyridine amifampridine phosphate (3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). As a reminder, BioMarin acquired the privately ...
  2 weeks ago

• A Sapphire Energy Co-Founder Sees Solutions in Algae for Drugs as Well as Biofuels

  
  Xconomy — Authority: 663
  Algae-based technologies , Drug Development , people Denise Gellene wrote: The potential of algae as a clean energy source has been generating a lot of entrepreneurial excitement in San Diego. At last count, 10 local companies are busy working on technologies focused on transforming ordinary pond scum ...
  2 weeks ago

• Panel of multiple sclerosis experts provides best practice treatment recommendations for Tysabri

  
  Science Blog - Science news straight from the source — Authority: 645
  Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis . The panel provided recommendations focusing on ...
  2 weeks ago

• Hyper-Analytical “Insanity” Cripples Drug R&D, Says Alnylam CEO John Maraganore

  
  Xconomy — Authority: 663
  Biotech , people , management Luke Timmerman wrote: There’s one thing drug makers love to use to figure out which drugs to invest in: spreadsheets. Not Alnylam Pharmaceuticals, though. Estimates of future cash flows and other financial analysis tools are one of the big reasons why drugmakers spend so ...
  2 weeks ago

Comments about idec